Last 7 days
8.8%
Last 30 days
17.4%
Last 90 days
-16.7%
Trailing 12 Months
-21%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 135.3B | 26.3B | -2.97% | 16.81% | 19.8 | 5.14 | 2.18% | 21.86% |
GILD | 105.0B | 27.1B | -0.99% | 30.15% | 31.49 | 3.87 | -1.26% | -54.91% |
MRNA | 73.3B | 21.4B | 7.28% | 27.41% | 6.23 | 3.43 | 80.80% | 66.62% |
BIIB | 41.9B | 10.4B | 5.85% | 32.49% | 14.62 | 4.04 | -6.64% | 85.32% |
NBIX | 10.4B | 1.4B | -8.79% | 49.41% | 178.74 | 7.49 | 29.86% | -86.92% |
MID-CAP | ||||||||
DNLI | 3.9B | - | 18.31% | 0.06% | -12.88 | 32.03 | -41.50% | -1123.42% |
BEAM | 3.2B | - | 23.33% | -24.11% | -10.12 | 59.51 | 215916.67% | 21.41% |
SMALL-CAP | ||||||||
RCUS | 1.7B | 432.8M | 17.41% | -21.00% | 20.97 | 3.87 | 1042.97% | 128.67% |
BBIO | 1.4B | - | 35.16% | 1.79% | -2.74 | 20.84 | 745.14% | 12.80% |
REPL | 1.3B | 3.1M | -3.43% | 39.57% | -8.78 | 417.83 | 7.05% | -46.74% |
NVAX | 886.0M | 1.8B | 24.61% | -84.52% | -0.67 | 0.48 | 53.41% | -22.97% |
FATE | 574.9M | 69.0M | -39.96% | -83.45% | -1.96 | 8.33 | 26.22% | -49.52% |
SGMO | 565.8M | 112.1M | 28.78% | -35.14% | -3.18 | 5.05 | 3.26% | 1.99% |
VXRT | 142.4M | - | 42.67% | -74.19% | -1.36 | 418.24 | -71.03% | -64.56% |
IBIO | 6.7M | - | 67.66% | -93.12% | -0.11 | 3.21 | 0.51% | -141.69% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | 5.9% | 433 | 409 | 391 | 383 | 38 |
Operating Expenses | 4.5% | 357 | 342 | 332 | 329 | 317 |
S&GA Expenses | 11.1% | 99 | 89 | 80 | 72 | 62 |
R&D Expenses | 2.2% | 258 | 252 | 251 | 256 | 255 |
EBITDA | 18.3% | 88 | 75 | -281.42 | 58 | - |
EBITDA Margin | 11.7% | 0.20* | 0.18* | -0.72* | 0.15* | - |
Earnings Before Taxes | 18.8% | 83 | 70 | 60 | 55 | -302.05 |
EBT Margin | 12.1% | 0.19* | 0.17* | -0.73* | 0.14* | - |
Net Income | 19.6% | 80 | 67 | 57 | 53 | -278.39 |
Net Income Margin | 12.9% | 0.18* | 0.16* | 0.15* | 0.14* | - |
Free Cahsflow | -4.6% | 432 | 452 | 439 | -282.25 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -5.6% | 1,394 | 1,477 | 1,543 | 1,592 | 839 |
Current Assets | -10.3% | 1,101 | 1,227 | 1,264 | 1,262 | 545 |
Cash Equivalents | -20.2% | 218 | 273 | 549 | 148 | 179 |
Net PPE | 1.4% | 34 | 33 | 33 | 32 | 29 |
Liabilities | -4.7% | 695 | 729 | 747 | 750 | 297 |
Current Liabilities | 8.0% | 177 | 164 | 161 | 166 | 143 |
Shareholder's Equity | -6.5% | 699 | 747 | 797 | 841 | 543 |
Retained Earnings | -15.8% | -474.90 | -409.98 | -343.35 | -275.35 | -554.72 |
Additional Paid-In Capital | 1.6% | 1,183 | 1,165 | 1,145 | 1,118 | 1,097 |
Accumulated Depreciation | - | 18 | - | - | - | - |
Shares Outstanding | 0.4% | 72 | 72 | 72 | 71 | 70 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -5.8% | 446 | 473 | 464 | -256.17 | -243.95 |
Share Based Compensation | 2.8% | 62 | 61 | 58 | 55 | 49 |
Cashflow From Investing | 20.3% | -440.90 | -552.95 | -334.75 | -3.87 | -23.01 |
Cashflow From Financing | 3.8% | 33 | 32 | 30 | 237 | 227 |
94.2%
94.2%
82.5%
Y-axis is the maximum loss one would have experienced if Arcus Biosciences was unfortunately bought at previous high price.
33.7%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-26 | OREGON PUBLIC EMPLOYEES RETIREMENT FUND | added | 0.45 | -93,429 | 358,571 | -% |
2023-01-26 | State of Tennessee, Treasury Department | added | 6.82 | 82,000 | 872,000 | -% |
2023-01-26 | COMERICA BANK | reduced | -21.87 | -474,000 | 630,000 | -% |
2023-01-26 | STRS OHIO | reduced | -19.94 | -313,000 | 539,000 | -% |
2023-01-26 | Inspire Investing, LLC | added | 44.81 | 30,186 | 236,186 | 0.03% |
2023-01-25 | Versant Capital Management, Inc | reduced | -16.67 | 207 | 207 | -% |
2023-01-25 | FIFTH THIRD BANCORP | unchanged | - | -3,248 | 13,752 | -% |
2023-01-24 | NATIONAL BANK OF CANADA /FI/ | unchanged | - | -933 | 2,067 | -% |
2023-01-24 | Louisiana State Employees Retirement System | unchanged | - | -136,000 | 513,000 | 0.01% |
2023-01-23 | Allspring Global Investments Holdings, LLC | reduced | -6.27 | -89,210 | 255,790 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jan 26, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 13.0% | 9,389,048 | SC 13G/A | |
Oct 17, 2022 | pfm health sciences, lp | 5.5% | 6 | SC 13G | |
May 09, 2022 | blackrock inc. | 11.1% | 7,967,677 | SC 13G | |
Mar 14, 2022 | biotechnology value fund l p | 3.0% | 2,156,510 | SC 13G | |
Feb 14, 2022 | gv 2016, l.p. | 0.91% | 638,967 | SC 13G/A | |
Feb 14, 2022 | pfm health sciences, lp | 4.9% | 6 | SC 13G/A | |
Feb 14, 2022 | ecor1 capital, llc | 7.9% | 5,523,358 | SC 13G/A | |
Feb 04, 2022 | blackrock inc. | 5.9% | 4,129,929 | SC 13G | |
Jul 19, 2021 | ecor1 capital, llc | 6.4% | 4,572,047 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
Jan 26, 2023 | SC 13G/A | Major Ownership Report | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 25, 2023 | 4 | Insider Trading | |
Jan 20, 2023 | SC 13G/A | Major Ownership Report | |
Dec 19, 2022 | 8-K | Current Report | |
Dec 16, 2022 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-23 | ROSEN TERRY J | acquired | - | - | 105,700 | chief executive officer |
2023-01-23 | Goeltz II Robert C. | acquired | - | - | 34,000 | chief financial officer |
2023-01-23 | Jarrett Jennifer | acquired | - | - | 45,800 | chief operating officer |
2023-01-23 | Nuyten Dimitry SA | acquired | - | - | 34,000 | chief medical officer |
2023-01-23 | Tang Carolyn C. | acquired | - | - | 34,000 | general counsel |
2023-01-23 | Jaen Juan C. | acquired | - | - | 45,800 | president |
2022-12-16 | ROSEN TERRY J | sold | -401,073 | 30.75 | -13,043 | chief executive officer |
2022-12-16 | Goeltz II Robert C. | sold | -75,429.6 | 30.7499 | -2,453 | chief financial officer |
2022-12-16 | Jarrett Jennifer | sold | -506,822 | 30.75 | -16,482 | chief operating officer |
2022-12-16 | Jaen Juan C. | sold | -136,407 | 30.7501 | -4,436 | president |
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Total revenues | $ 33,581 | $ 9,461 | $ 78,345 | $ 28,383 |
Operating expenses: | ||||
Research and development (($26,560), ($756), ($92,667) and ($6,856) from a related party) | 76,684 | 71,254 | 207,800 | 206,412 |
General and administrative (($493), $0, ($690) and $0 from a related party) | 26,294 | 16,343 | 76,104 | 48,990 |
Total operating expenses | 102,978 | 87,597 | 283,904 | 255,402 |
Loss from operations | (69,397) | (78,136) | (205,559) | (227,019) |
Non-operating income (expense): | ||||
Interest and other income, net | 5,013 | 161 | 8,456 | 481 |
Effective interest on liability for sale of future royalties | (535) | (1,437) | ||
Total non-operating income, net | 4,478 | 161 | 7,019 | 481 |
Net loss before income taxes | (64,919) | (77,975) | (198,540) | (226,538) |
Income tax expense | 0 | 0 | (1,004) | 0 |
Net loss | (64,919) | (77,975) | (199,544) | (226,538) |
Other comprehensive loss | (2,557) | (46) | (8,540) | (136) |
Comprehensive loss | $ (67,476) | $ (78,021) | $ (208,084) | $ (226,674) |
Net loss per share, basic | $ (0.90) | $ (1.11) | $ (2.78) | $ (3.28) |
Net loss per share, diluted | $ (0.90) | $ (1.11) | $ (2.78) | $ (3.28) |
Weighted-average number of shares used to compute basic net loss per share | 72,236,283 | 70,110,138 | 71,752,246 | 68,990,290 |
Weighted-average number of shares used to compute diluted net loss per share | 72,236,283 | 70,110,138 | 71,752,246 | 68,990,290 |
License and Development Services Revenue | ||||
Revenues: | ||||
Total revenues | $ 23,742 | $ 48,374 | ||
Other Collaboration Revenue | ||||
Revenues: | ||||
Total revenues | $ 9,839 | $ 9,461 | $ 29,971 | $ 28,383 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 |
---|---|---|---|
Current assets: | |||
Cash and cash equivalents | $ 217,647 | $ 147,914 | |
Short-term investments | 831,135 | 351,394 | |
Receivable from collaboration partners ($26,521 and $744,535 from a related party) | 27,286 | 744,595 | |
Accrued interest receivable | 3,423 | 2,227 | |
Prepaid expenses and other current assets | 21,625 | 15,620 | |
Total current assets | 1,101,116 | 1,261,750 | |
Long-term investments | 143,138 | 181,990 | |
Property and equipment, net | 33,892 | 32,455 | |
Right-of-use assets | 102,073 | 104,968 | |
Restricted cash | 3,005 | 3,005 | |
Other long-term assets ($1,856 and $0 from a related party) | 10,598 | 7,730 | |
Total assets | 1,393,822 | 1,591,898 | |
Current liabilities: | |||
Accounts payable | 10,546 | 10,261 | |
Accrued research and development | 39,827 | 29,587 | |
Other accrued liabilities | 20,528 | 24,181 | |
Deferred revenue, current ($103,291 and $96,981 to a related party) | 103,291 | 102,003 | |
Other current liabilities | 2,984 | 52 | |
Total current liabilities | 177,176 | 166,084 | |
Deferred revenue, noncurrent ($382,584 and $462,217 to a related party) | 382,584 | 462,217 | |
Operating lease liabilities, noncurrent | 119,195 | 116,887 | |
Other long-term liabilities | 16,166 | 5,260 | |
Total liabilities | 695,121 | 750,448 | |
Commitments (Note 11) | |||
Stockholders’ equity: | |||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | 0 | 0 | |
Common stock, $0.0001 par value, 400,000,000 shares authorized; 72,352,380 and 70,781,736 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively. Shares outstanding includes zero and 9,946 shares issued but subject to vesting as of September 30, 2022 and December 31, 2021, respectively | 7 | 7 | |
Additional paid-in capital | 1,183,393 | 1,118,058 | |
Accumulated deficit | (474,898) | (275,354) | |
Accumulated other comprehensive loss | (9,801) | (1,261) | |
Total stockholders’ equity | 698,701 | $ 747,386 | 841,450 |
Total liabilities and stockholders’ equity | $ 1,393,822 | $ 1,591,898 |